Xenetic Biosciences Statistics
Total Valuation
XBIO has a market cap or net worth of $6.41 million. The enterprise value is -$932,298.
| Market Cap | 6.41M |
| Enterprise Value | -932,298 |
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBIO has 2.29 million shares outstanding. The number of shares has increased by 22.51% in one year.
| Current Share Class | 2.29M |
| Shares Outstanding | 2.29M |
| Shares Change (YoY) | +22.51% |
| Shares Change (QoQ) | +5.10% |
| Owned by Insiders (%) | 8.17% |
| Owned by Institutions (%) | 5.56% |
| Float | 1.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.01 |
| Forward PS | n/a |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.93
| Current Ratio | 7.93 |
| Quick Ratio | 7.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.01% and return on invested capital (ROIC) is -24.79%.
| Return on Equity (ROE) | -37.01% |
| Return on Assets (ROA) | -21.85% |
| Return on Invested Capital (ROIC) | -24.79% |
| Return on Capital Employed (ROCE) | -34.45% |
| Weighted Average Cost of Capital (WACC) | 16.32% |
| Revenue Per Employee | $1.60M |
| Profits Per Employee | -$1.12M |
| Employee Count | 2 |
| Asset Turnover | 0.47 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.19% in the last 52 weeks. The beta is 2.19, so XBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | +2.19% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 2.95 |
| Relative Strength Index (RSI) | 38.41 |
| Average Volume (20 Days) | 19,319 |
Short Selling Information
The latest short interest is 16,388, so 0.72% of the outstanding shares have been sold short.
| Short Interest | 16,388 |
| Short Previous Month | 5,914 |
| Short % of Shares Out | 0.72% |
| Short % of Float | 0.90% |
| Short Ratio (days to cover) | 1.46 |
Income Statement
In the last 12 months, XBIO had revenue of $3.19 million and -$2.23 million in losses. Loss per share was -$1.18.
| Revenue | 3.19M |
| Gross Profit | 3.19M |
| Operating Income | -2.39M |
| Pretax Income | -2.23M |
| Net Income | -2.23M |
| EBITDA | n/a |
| EBIT | -2.39M |
| Loss Per Share | -$1.18 |
Balance Sheet
The company has $7.35 million in cash and n/a in debt, with a net cash position of $7.35 million or $3.21 per share.
| Cash & Cash Equivalents | 7.35M |
| Total Debt | n/a |
| Net Cash | 7.35M |
| Net Cash Per Share | $3.21 |
| Equity (Book Value) | 6.95M |
| Book Value Per Share | 3.03 |
| Working Capital | 6.64M |
Cash Flow
| Operating Cash Flow | -1.82M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -1.82M |
| FCF Per Share | -$0.79 |
Margins
Gross margin is 100.00%, with operating and profit margins of -75.05% and -70.03%.
| Gross Margin | 100.00% |
| Operating Margin | -75.05% |
| Pretax Margin | -70.03% |
| Profit Margin | -70.03% |
| EBITDA Margin | n/a |
| EBIT Margin | -75.05% |
| FCF Margin | n/a |
Dividends & Yields
XBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.51% |
| Shareholder Yield | -22.51% |
| Earnings Yield | -34.83% |
| FCF Yield | -28.39% |
Analyst Forecast
The average price target for XBIO is $40.00, which is 1,328.57% higher than the current price. The consensus rating is "Hold".
| Price Target | $40.00 |
| Price Target Difference | 1,328.57% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | 49.04% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 15, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
XBIO has an Altman Z-Score of -31.6 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -31.6 |
| Piotroski F-Score | 2 |